摘要
目的 :研究凝血酶原前体蛋白 (Prescursorofprothrombin ,Pro teinsInducedbyVitaminKAbsenseofAntagonism ,PIVKA Ⅱ )在华法林抗凝效果监测中的应用。方法 :选取口服华法林抗凝治疗 5天以上的住院患者 3 4例测定PT、INR、FIB及PIVKA Ⅱ含量 ,并与正常对照组 2 5例作比较。结果 :华法林抗凝组PIVKA Ⅱ、PT、INR结果显著高于正常对照组 (P <0 .0 1) ,两组标本FIB含量无显著性差异(P >0 .0 5 )。PIVKA Ⅱ、PT、INR三者呈直线正相关 (P <0 .0 5 ) ,其与FIB之间相关性无统计学意义 (P >0 .0 5 )。结论 :同时测定PT、INR与PIVKA
Objective: To investigate the application of Precursor of Prothrombin in monitoring of anticoagulation effect for warfarin.Method: 34 patients were treated by warfarin for more than 5 days were selected into the study,the level of PT,INR,FIB and precursor of prothrombin were measured and compared with normal control group.Results: Compared with normal control group,Precursor of prothrombin,PT and INR were elevated( P<0.01 ).The difference of FIB between two groups were not significance( P>0.05 ).Good correlations were observed between Precursor of Prothrombin,PT and INR( P<0.05 ).Conclusion: Simultaneous measurement of PT,INR and Precursor of Prothrombin are better to improve the accuracy of anticoagulation effect monitering of warfarin.
出处
《微循环学杂志》
2003年第3期36-37,共2页
Chinese Journal of Microcirculation
关键词
凝血酶原前体蛋白
华法林
抗凝效果
监测
临床应用
抗凝剂
Precursor of prothormbin(PIVKA Ⅱ)
Prothrombin time(PT)
International normalized ratio(INR)
Warfarin